

OIPE JCSA

 MAR 25 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Typed or Printed Name

Signature

Date

RECEIVED

APR 01 2003

RESPONSE TO RESTRICTION REQUIREMENT

Address to:
Commissioner for Patents
Washington, D.C. 20231

Attorney Docket
(Confirmation No.)

STAN010CON
1876

First Named Inventor

S.N. Cohen

TECH CENTER 1600/2900

Application Number

09/804,690

Filing Date

March 12, 2001

Group Art Unit

1642

Examiner Name

M. Yu

Title: *Mammalian susceptibility genes and their uses*

Sir:

This is in response to the Restriction Requirement dated October 1, 2002. The Restriction Requirement set forth a one-month time period for response, making a response due on or before November 1, 2002. ***A Petition for a five-Month Extension of Time is submitted herewith, making this amendment due on or before April 1, 2003.*** Accordingly, this response is timely filed.

I. REMARKS

In the Office Action dated October 1, 2002, all claims appear to be numbered incorrectly by the Examiner. Specifically, claims 24-50 are incorrectly referred to as claims 23-49, respectively. In the instant response, Applicants have used the correct numbering of pending claims 24-50 as set forth in the preliminary amendment filed on June 7, 2001.

In the Restriction Requirement, the Examiner required election of one of the following groups of claims:

- Group I: Claims 24-28, drawn to antibody to wild-type TSG 101;
- Group II: Claims 29-32, drawn to antibody to mutant TSG 101;
- Group III: Claims 33-36, in part, drawn to antibody wild-type coiled coil domain of TSG101;
- Group IV: Claims 33-36 in part, drawn to antibody to mutant-type coiled coil domain of TSG101;
- Group V: Claims 37-40 in part, drawn to antibody to wild-type leucine zipper domain of TSG101,
- Group VI: Claims 37-40 in part, drawn to antibody to mutant-type leucine zipper domain of TSG101;
- Group VII: Claims 41-44 in part, drawn to antibody to wild-type proline domain of TSG101;
- Group VIII: Claims 41-44 in part, drawn to antibody to mutant-type proline domain of TSG101;
- Group IX: Claims 45 in part, 46 in part, drawn to method of cancer diagnosis using Group II product above;
- Group X: Claims 45 in part, 46 in part drawn to method of cancer diagnosis using Group IV product above;
- Group XI: Claims 45 in part, 46-50, drawn to method of cancer diagnosis using Group VI product above; and

 15
 10
 4/30/03